β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging.
Mrinmoy MaitiKai KikuchiK K AthulAmandeep KaurSankarprasad BhuniyaPublished in: Chemical communications (Cambridge, England) (2022)
A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.
Keyphrases
- fluorescence imaging
- cell death
- cancer therapy
- photodynamic therapy
- drug delivery
- living cells
- cell cycle arrest
- fluorescent probe
- quantum dots
- high resolution
- sensitive detection
- locally advanced
- mesenchymal stem cells
- cell proliferation
- radiation therapy
- signaling pathway
- drug release
- stem cells
- bone marrow
- label free
- social media
- replacement therapy